- Home
- NEUP vs NXTC Comparison
NEUP vs NXTC Comparison
Compare NEUP & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- NXTC
- Stock Information
- Founded
- NEUP 1996
- NXTC 2015
- Country
- NEUP United States
- NXTC United States
- Employees
- NEUP N/A
- NXTC N/A
- Industry
- NEUP
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- NXTC Health Care
- Exchange
- NEUP Nasdaq
- NXTC Nasdaq
- Market Cap
- NEUP 9.3M
- NXTC 9.3M
- IPO Year
- NEUP N/A
- NXTC 2019
- Fundamental
- Price
- NEUP $4.74
- NXTC $0.41
- Analyst Decision
- NEUP Strong Buy
- NXTC Strong Buy
- Analyst Count
- NEUP 1
- NXTC 2
- Target Price
- NEUP $21.00
- NXTC $3.50
- AVG Volume (30 Days)
- NEUP 10.9K
- NXTC 178.3K
- Earning Date
- NEUP 05-23-2025
- NXTC 05-01-2025
- Dividend Yield
- NEUP N/A
- NXTC N/A
- EPS Growth
- NEUP N/A
- NXTC N/A
- EPS
- NEUP N/A
- NXTC N/A
- Revenue
- NEUP $662,715.00
- NXTC N/A
- Revenue This Year
- NEUP N/A
- NXTC N/A
- Revenue Next Year
- NEUP N/A
- NXTC N/A
- P/E Ratio
- NEUP N/A
- NXTC N/A
- Revenue Growth
- NEUP N/A
- NXTC N/A
- 52 Week Low
- NEUP $2.12
- NXTC $0.22
- 52 Week High
- NEUP $15.24
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- NXTC 45.41
- Support Level
- NEUP N/A
- NXTC $0.34
- Resistance Level
- NEUP N/A
- NXTC $0.47
- Average True Range (ATR)
- NEUP 0.00
- NXTC 0.06
- MACD
- NEUP 0.00
- NXTC 0.01
- Stochastic Oscillator
- NEUP 0.00
- NXTC 39.66
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.